---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-161601"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:23:23.765579+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Lyell Immunopharma holds 2024 annual meeting; all proposals approved

## Summary
- Elected Elizabeth Nabel (147.8M for, 16.2M withheld) and Lynn Seely (150.1M for, 13.9M withheld) as Class III directors.
- Ratified Ernst & Young as auditor for FY2024 with 198.6M votes for, 153.7K against, 57K abstentions.
- Advisory say-on-pay approved: 108.8M for, 47.0M against, 8.2M abstentions; broker non-votes 34.8M.
- Quorum of 77.98% (198.8M shares) represented at the June 14, 2024 virtual meeting.

## SEC filing metadata
- accession: 0001193125-24-161601
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000119312524161601/0001193125-24-161601-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000119312524161601/d855288d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-161601
- JSON: https://secwatch.observer/filing/0001193125-24-161601.json
- Plain text: https://secwatch.observer/filing/0001193125-24-161601.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.